SOUTH SAN FRANCISCO, Calif., Sept. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will present data suggesting improved one-year survival with ZYBRESTAT compared to historical survival rates in patients with anaplastic thyroid cancer (ATC) at the upcoming 35th Meeting of the European Thyroid Association, in Krakow, Poland on September 14, 2011. OXiGENE will release a summary of results immediately after they are presented.
